Noticia Ricardo Sainz Psious

Ricardo Sáinz new Chief Medical Officer (CMO) at Psious

Ricardo Sáinz new Chief Medical Officer (CMO) at Psious

  • The new Chief Medical Officer of the company has two decades of experience in psychiatric care and supervision as well as in scientific research
  • Ricardo Sáinz’s incorporation reinforces Psious’s strategic commitment to lead scientific research in digital therapeutics and virtual reality

Ricardo Sáinz Fuertes has been appointed Chief Medical Officer (CMO) of Psious, a company specialized in Digital Therapeutics (DTx) and Virtual Reality (VR) applied to mental health, with the objective of leading scientific research at Psious.

Psychiatric doctor with a Doctorate in Neuroscience (Ph.D.) and a Master in Research Methods in Psychiatry (MSc) at Kings College London, Ricardo Sáinz has two decades of clinical experience in psychiatric care, clinical supervision, and scientific research. One of the most notable positions in his career is that of Consultant Psychiatrist in the National Health Service of the United Kingdom (NHS) as well as in private care services. Sáinz has also been a Specialist Advisor for the Care Quality Commission (CQC), the independent regulator of healthcare in the United Kingdom. In 2016, his professional career then changed course towards the pharmaceutical industry where he held the position of EU Medical Manager (Psychiatry and Neurology) in the pharmaceutical company Otsuka.

The new CMO of Psious will be responsible for scientific research and will lead the company’s future clinical and research strategies. Xavier Palomer, CEO of Psious, values ​​the latest incorporation very positively as it will provide greater scientific validation: “The arrival of Ricardo Sáinz as the clinical director is another step forward in the commitment of Psious towards offering a ‘digital therapeutics’ solution that meets the highest standards in terms of empirical evidence. All the treatments included in our Virtual Reality platform for mental health are based on scientific studies carried out by the most prestigious institutions during the last 25 years ”.

Ricardo Sáinz’s incorporation is part of the company’s plan for expansion and development after the closure of an 8-million-euro funding round from Sabadell Venture Capital, Caixa Capital Risc and Sabadell Asabys last May. Among the objectives of the funding received is the development of virtual reality software at Psious, more clinical research and the international growth of the startup.